$NVCT NXP800 shows strong activity in ARID1a target w/ 1/3 PRs/100% DCR. What was very surprising was that it achieved the CR in non-target lymph node disease. This is a very positive outcome & indicates a high level of efficacy & demonstrates GCN2-mediated chronic ISR activation
2
2
11
7K
2
Download Image
@JD4for4 lymph nodes are where the disease resides, so calling it off target may be techincally correct but misses the relevance and importance